-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 12, vTv Therapeutics announced that the study of the mechanism of TTP399 in the treatment of type 1 diabetes has obtained positive results, proving that patients with type 1 diabetes who received TTP399 did not have an increase in keto acid levels during the withdrawal of insulin treatment compared with the placebo group, which means that TTP399 does not Increase the risk of ketoacidosis
The mechanism study enrolled 23 patients with type 1 diabetes who are using insulin pumps and were randomized to receive TP399 (n=12) or placebo (n=11) once a day for approximately 7 days
Consistent with previous studies, TTP399 can improve fasting blood glucose control, and there were no hypoglycemia events in the TTP399 treatment group one week before the insulin withdrawal test, and 4 hypoglycemia events in the placebo control group
The FDA previously refused to approve SGLT-2 inhibitors as an adjuvant therapy for T1D patients, mainly because of concerns about the risk of diabetic ketoacidity (DKA)
TTP399 is a selective glucokinase agonist.
